ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 614.38M | 555.46M | 538.95M | 517.46M | 486.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 614.38M | 555.46M | 538.95M | 517.46M | 486.82M |
| Cost of Revenue | 250.21M | 223.35M | 208.38M | 192.96M | 181.51M |
| Gross Profit | 364.17M | 332.11M | 330.58M | 324.50M | 305.30M |
| SG&A Expenses | 237.24M | 212.18M | 183.91M | 173.25M | 161.70M |
| Depreciation & Amortization | 67.73M | 60.33M | 59.78M | 59.78M | 59.79M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 599.76M | 533.66M | 490.87M | 464.86M | 437.29M |
| Operating Income | 14.62M | 21.80M | 48.09M | 52.60M | 49.53M |
| Income Before Tax | -22.21M | -7.50M | 35.51M | 43.04M | 19.87M |
| Income Tax Expenses | -3.69M | -412.00K | 8.49M | 7.50M | 1.09M |
| Earnings from Continuing Operations | -18.52 | -7.09 | 27.02 | 35.55 | 18.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.52M | -7.09M | 27.02M | 35.55M | 18.78M |
| EBIT | 14.62M | 21.80M | 48.09M | 52.60M | 49.53M |
| EBITDA | 82.35M | 82.13M | 107.87M | 112.38M | 109.32M |
| EPS Basic | -1.02 | -0.44 | 1.29 | 1.63 | 0.85 |
| Normalized Basic EPS | -0.22 | 0.07 | 0.87 | 0.96 | 0.78 |
| EPS Diluted | -1.04 | -0.45 | 1.27 | 1.60 | 0.83 |
| Normalized Diluted EPS | -0.23 | 0.06 | 0.86 | 0.94 | 0.77 |
| Average Basic Shares Outstanding | 77.27M | 76.83M | 76.31M | 74.67M | 71.97M |
| Average Diluted Shares Outstanding | 77.59M | 77.37M | 77.09M | 75.62M | 72.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -8.77% | -22.92% | 6.02% | 4.57% | 8.65% |
